Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
26 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
124.6 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CHU LA MILETRIE
2 R DE LA MILETRIE CS 90577, 86021 POITIERS CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
BMC cancer · 2022
Abstract Background Metastasis-directed therapy (MDT) significantly delays the initiation of palliative androgen deprivation therapy (pADT) in patients with oligorecurrent prostate cancer (PCa) with a positive impact on patient’s quality of life. However, it remains unclear whether the addition of ADT improves polymetastatic free survival (PMFS) and metastatic castration refractory PCa-free survival (mCRPC-FS) and how long concomitant hormone therapy should be given. A significant overall survival (OS) benefit was shown when an androgen receptor targeted agent (ARTA) was added to pADT in patients with metastatic hormone sensitive PCa (HSPC). However, whether the addition of and ARTA to MDT in the treatment of oligorecurrent PCa results in better PMFS and mCRPC-FS has not been proven yet. Methods & design Patients diagnosed with oligorecurrent HSPC (defined as a maximum of 5 extracranial metastases on PSMA PET-CT) will be randomized in a 1:1:1 allocation ratio between arm A: MDT alone, arm B: MDT with 1 month ADT, or arm C: MDT with 6 months ADT together with ARTA (enzalutamide 4 × 40 mg daily) for 6 months. Patients will be stratified by PSA doubling time (≤ 3 vs. > 3 months), number of metastases (1 vs. > 1) and initial localization of metastases (M1a vs. M1b and/or M1c). The primary endpoint is PMFS, and the secondary endpoints include mCRPC-FS, biochemical relapse-free survival (bRFS), clinical progression free survival (cPFS), cancer specific survival (CSS), overall survival (OS), quality of life (QOL) and toxicity. Discussion This is the first prospective multicentre randomized phase III trial that investigates whether the addition of short-term ADT during 1 month or short-term ADT during 6 months together with an ARTA to MDT significantly prolongs PMFS and/or mCRPC-FS. Trial registration ClinicalTrials.gov Identifier: NCT05352178, registered April 28, 2022.
Cancers · 2023
Background: Tumour apparent diffusion coefficient (ADC) from diffusion-weighted magnetic resonance imaging (MRI) is a putative pharmacodynamic/response biomarker but the relationship between drug-induced effects on the ADC and on the underlying pathology has not been adequately defined. Hypothesis: Changes in ADC during early chemotherapy reflect underlying histological markers of tumour response as measured by tumour regression grade (TRG). Methods: Twenty-six patients were enrolled in the study. Baseline, 14 days, and pre-surgery MRI were performed per study protocol. Surgical resection was performed in 23 of the enrolled patients; imaging-pathological correlation was obtained from 39 lesions from 21 patients. Results: There was no evidence of correlation between TRG and ADC changes at day 14 (study primary endpoint), and no significant correlation with other ADC metrics. In scans acquired one week prior to surgery, there was no significant correlation between ADC metrics and percentage of viable tumour, percentage necrosis, percentage fibrosis, or Ki67 index. Conclusions: Our hypothesis was not supported by the data. The lack of meaningful correlation between change in ADC and TRG is a robust finding which is not explained by variability or small sample size. Change in ADC is not a proxy for TRG in metastatic colorectal cancer.
Cancers · 2024
Gastric cancer (GC) is a major cause of cancer-related mortality worldwide. It is often associated with a bad prognosis because of its asymptomatic phenotype until advanced stages, highlighting the need for its prevention and early detection. GC development is preceded by the emergence of gastric preneoplasia lesions (GPNLs), namely atrophic gastritis (AG), intestinal metaplasia (IM), and dysplasia (DYS). GC is currently diagnosed by endoscopy, which is invasive and costly and has limited effectiveness for the detection of GPNLs. Therefore, the discovery of non-invasive biomarkers in liquid biopsies, such as blood samples, in order to identify the presence of gastric preneoplasia and/or cancer lesions at asymptomatic stages is of paramount interest. This comprehensive review provides an overview of recently identified plasma/serum proteins and their diagnostic performance for the prediction of GPNLs and early cancer lesions. Autoantibodies appear to be promising biomarkers for AG, IM and early gastric cancer detection, along with inflammation and immunity-related proteins and antibodies against H. pylori virulence factors. There is a lack of specific protein biomarkers with which to detect DYS. Despite the need for further investigation and validation, some emerging candidates could pave the way for the development of reliable, non-invasive diagnostic tests for the detection and prevention of GC.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Studies in health technology and informatics · 2026 · Journal Article
Flobinus S, Cecilia-Joseph E, Pierre-Jean M, Sanchez K, et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025 · Journal Article
Lucie L, Sarah L, Laurène J, Louise T, et al.
BMC research notes · 2025 · Journal Article
Maxime B, Jérôme A, Francisco O, Alexis S, et al.
Cureus · 2025 · Journal Article
J N, Gunabooshanam B, Balasubramanian S
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2024 · Journal Article
Julie G, Manon BDN, Charles Henri FL, Giuseppe R, et al.
BMC cancer · 2022 · Randomized Controlled Trial
Rans K, Charlien B, Filip A, Olivier H, et al.
The American journal of emergency medicine · 2022 · Journal Article
Manoukian MAC, Rose JS, Brown SK, Wynia EH, et al.
Neuro-Chirurgie · 2026 · Journal Article
Valentin A, Stéphane F, Mikael M, Adrien M, et al.
Health economics review · 2025 · Journal Article
Shobha V, Singhai S, Haridas V, V S, et al.
Cancers · 2024 · Journal Article
Bazin T, Nozeret K, Julié C, Lamarque D, et al.
The Review of scientific instruments · 2024 · Journal Article
Swami R, Julié G, Le-Denmat S, Pernot G, et al.
Journal of ISAKOS : joint disorders & orthopaedic sports medicine · 2026 · Journal Article
Martinique VB, Julie H, Snorre S, Soeren R, et al.
Cureus · 2024 · Journal Article
Kg G, J R
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · Journal Article
Illini O, Hund AC, Kopp HG, Moskovitz M, et al.
Pharmacoepidemiology and drug safety · 2025 · Journal Article
Julie R, Yael B, Anaïs H, Anne T, et al.
Comprehensive psychiatry · 2025 · Journal Article
Julie F, Vrutti J, Jonathan DM
JMIR neurotechnology · 2023 · Journal Article
Andrews JA, Craven MP, Guo B, Weyer J, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · Journal Article
Illini O, Hund AC, Kopp HG, Moskovitz M, et al.
JMIR public health and surveillance · 2022 · Observational Study
Sylvestre E, Cécilia-Joseph E, Bouzillé G, Najioullah F, et al.
Journal of ISAKOS : joint disorders & orthopaedic sports medicine · 2026 · Journal Article
Martinique VB, Julie H, Snorre S, Soeren R, et al.
Cancers · 2023 · Journal Article
Jackson A, Pathak R, deSouza NM, Liu Y, et al.
International journal of surgery (London, England) · 2024 · Journal Article
Mekkan-Bouv Hez M, Derbey L, de Mestier L, Lorenzo D, et al.
Ear and hearing · 2026 · Journal Article
Quatre R, Baguant A, Renard F, Lalami G, et al.
Ear and hearing · 2026 · Journal Article
Quatre R, Baguant A, Renard F, Lalami G, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Chandwani A, J S, Dwivedi A, Sivasami K, et al.
Hip & pelvis · 2024 · Journal Article
Ansari S, Gupta K, Gupta T, Raja BS, et al.
Cureus · 2025 · Case Reports
K R, J P, R R, B V MM, et al.
Cureus · 2023 · Journal Article
J S, S L, Nair MV, R KT, et al.
Cureus · 2023 · Case Reports
J SK, Waheed MD, Batool S, Holder SS, et al.
Hip & pelvis · 2024 · Journal Article
Ansari S, Gupta K, Gupta T, Raja BS, et al.